SEC Form 4 · accession 0001562180-18-001842
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO & Treasurer
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $145.77 | Apr 2, 2018 | A | 31,500 | A | — | Apr 2, 2028 | Common Stock | 31,500 | 31,500 | D |
Explanation of responses
- F1The securities awarded on 4/2/2018 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,938 shares of common stock shall vest on the one year anniversary of the 2/1/2018 Vesting Start Date with 11,812 shares vesting in 36 equal monthly installments thereafter. Options to purchase 15,750 shares of common stock shall vest periodically upon the Company achieving certain milestones.